v3.26.1
Share-based compensation plan - Phantom shares plan ("PS") and Restricted Shares (Details)
 6 Months Ended 12 Months Ended
Jun. 30, 2026
BRL (R$)
shares
R$ / shares
shares
Dec. 31, 2025
BRL (R$)
shares
Dec. 31, 2024
BRL (R$)
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Non-current provisions for employee benefits | R$ R$ 304,921,000 R$ 332,322,000  
PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 10,584,875 9,053,407  
Shares granted 2,971,507    
Cancelled 319,350    
Exercised (1) 1,120,689    
Available for completion 65,308    
Restricted stock, year one 1,811,817    
Restricted stock, year two 2,481,490    
Restricted stock, year three 3,555,190    
Restricted stock, year four 2,671,070    
Non-current provisions for employee benefits | R$ R$ 304,921,000 R$ 332,322,000 R$ 361,974,000
Increase Provision Share Based Payment | R$ 39,673,000 209,842,000  
Decrease Provision Share Based Payment Cancelled | R$ (7,891,000) (17,843,000)  
Decrease Provision Share Based Payment | R$ R$ (59,183,000) R$ (221,651,000)  
Phantom Share Units Psus      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Phantom Share Units Psus | R$ / shares R$ 47.79    
Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 3,092,957 3,076,116  
Shares granted 532,774    
Exercised (1) 515,933    
Restricted stock, year one 440,715    
Restricted stock, year two 235,794    
Restricted stock, year three 1,982,244    
Restricted stock, year four 241,637    
Restricted stock, year five 192,567    
Non-current provisions for employee benefits | R$ R$ 76,870,000 R$ 80,742,000 R$ 60,226,000
Increase Provision Share Based Payment | R$ 23,159,000 45,642,000  
Decrease Provision Share Based Payment | R$ (27,031,000) R$ (25,126,000)  
Grant Year 2021 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 64.12    
Number of other equity instruments outstanding in share-based payment arrangement 7,735  
Shares granted 168    
Exercised (1) 7,903    
Grant Year 2022 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 54.20    
Number of other equity instruments outstanding in share-based payment arrangement 137,194 480,184  
Shares granted 10,447    
Cancelled 221    
Exercised (1) 353,216    
Available for completion 65,308    
Restricted stock, year one 47,391    
Restricted stock, year two 24,495    
Grant Year 2023 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 48.81    
Number of other equity instruments outstanding in share-based payment arrangement 2,012,762 2,695,561  
Shares granted 58,994    
Cancelled 37,419    
Exercised (1) 704,374    
Restricted stock, year one 1,764,426    
Restricted stock, year two 248,336    
Grant Year 2023 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 50.51    
Number of other equity instruments outstanding in share-based payment arrangement 277,249  
Shares granted 6,033    
Exercised (1) 283,282    
Grant Year 2024 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 56.58    
Number of other equity instruments outstanding in share-based payment arrangement 2,374,898 2,459,390  
Shares granted 53,332    
Cancelled 114,998    
Exercised (1) 22,826    
Restricted stock, year two 2,208,659    
Restricted stock, year three 166,239    
Grant Year 2024 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 56.09    
Number of other equity instruments outstanding in share-based payment arrangement 2,149,682 2,331,602  
Shares granted 50,731    
Exercised (1) 232,651    
Restricted stock, year one 440,715    
Restricted stock, year three 1,708,967    
Grant Year 2025 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 59.65    
Number of other equity instruments outstanding in share-based payment arrangement 3,388,951 3,410,537  
Shares granted 148,358    
Cancelled 143,709    
Exercised (1) 26,235    
Restricted stock, year three 3,388,951    
Grant Year 2025 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 60.47    
Number of other equity instruments outstanding in share-based payment arrangement 477,431 467,265  
Shares granted 10,166    
Restricted stock, year two 235,794    
Restricted stock, year four 241,637    
Grant Year 2026 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 51.58    
Number of other equity instruments outstanding in share-based payment arrangement 2,671,070    
Shares granted 2,700,208    
Cancelled 23,003    
Exercised (1) 6,135    
Restricted stock, year four 2,671,070    
Grant Year 2026 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$ R$ 51.09    
Number of other equity instruments outstanding in share-based payment arrangement 465,844    
Shares granted 465,844    
Restricted stock, year three 273,277    
Restricted stock, year five 192,567